You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 39 No. 6, June 1982 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Antipsychotic Properties of Des-Enkephalin-{gamma}-Endorphin in Treatment of Schizophrenic Patients

Wim M. A. Verhoeven, MD; Jan M. van Ree, MD; Ans Heezius-van Bentum, MD; David de Wied, MD; Herman M. van Praag, MD

Arch Gen Psychiatry. 1982;39(6):648-654.


Abstract

• Animal experiments have shown that the {gamma}-endorphin fragment des-enkephalin-{gamma}-endorphin (DE{gamma}E; β-lipotropin 66-77) is the shortest sequence with neuroleptic-like activity with potency comparable to des-tyrosine-{gamma}-endorphin. We postulated that DE{gamma}E may be an endogenous peptide implicated in psychopathologic disease, particularly schizophrenia. To investigate the purported antipsychotic action of DE{gamma}E, 23 patients with different types of relapsing schizophrenia were treated with DE{gamma}E dissolved in saline or placebo. Neuroleptic medication was continued during the experimental period. In the first singleblind trial, two patients were treated with 1 mg of DE{gamma}E and two with 10 mg of DE{gamma}E intramuscularly (IM) daily for ten days. In the second double-blind placebo-controlled trial 13 patients were treated with 3 mg of DE{gamma}E IM daily for ten days and six received placebo. Of the 17 patients treated with DE{gamma}E, two did not respond, 11 had a slight to moderate effect, and four responded markedly. No side effects were observed. The response to DE{gamma}E appeared to be negatively correlated with the dosage of neuroleptic medication and the duration of the last psychotic episode. These results support the hypothesis that disturbances in {gamma}-endorphin fragmentation might contribute to the pathogenesis of schizophrenic psychoses.



Author Affiliations

From the Department of Psychiatry, State University, Utrecht (Drs Verhoeven and van Praag), Rudolf Magnus Institute for Pharmacology, Utrecht (Drs van Ree and de Wied), and Wolfheze Psychiatric Hospital (Dr Heezius-van Bentum), the Netherlands.


Footnotes

Accepted for publication Dec 11, 1981.

Reprint requests to Department of Psychiatry, State University, Nicolaas Beetsstraat 24, Utrecht, the Netherlands (Dr Verhoeven).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.